Medicines Patent Pool Launches Search For Next Director 08/01/2018 by William New, Intellectual Property Watch Leave a Comment A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement.
WHO’s Revised Work Programme: Evidence-Based Normative Work, Access To Medicines 08/01/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment In a couple of weeks, the World Health Organization will be holding its annual January Executive Board meeting. Delegates will consider the edited version of the draft 13th WHO general programme of work for 2019-2023, published on 5 January. Following comments to the first version of the programme in November, the secretariat produced a more fleshed-out document, emphasizing the WHO’s normative role, in particular evidence-based. The necessity of access to medicines and vaccines has been extended to other products, such as devices and blood products, and mention is made of the WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property.
Top IP-Watch Stories Of 2017: What Do They Tell Us About Multilateral IP Policy? 04/01/2018 by William New, Intellectual Property Watch 1 Comment What IP-Watch stories were readers reading most in 2017, and what does it say about the state of global intellectual property policy? In this article, we look at the most-trafficked stories of last year, and make a few assumptions. Asia, Europe, trade, health. These were the top targets of interest to readers among our offerings. Interestingly, despite all the sound and fury in Washington, our coverage there was not at the top of the list. Even more interestingly, neither was our extensive and world-leading coverage of the World Intellectual Property Organization.
A Canadian Billionaire’s Mysterious Death And The Effect On Access To Medicines 20/12/2017 by William New, Intellectual Property Watch Leave a Comment The mysterious death last week of Canadian billionaire Barry Sherman and his wife has raised many questions. For some, one question is what impact it will have on pharmaceutical competition in Canada, as his giant generic medicines company Apotex was seen as making a mark in access to medicines. It was also recalled that the company is the only one to have used an obscure provision of a World Trade Organization intellectual property agreement aimed at making more affordable medicines available in least developed countries.
WIPO Patent Law Committee Agrees On Future Work, Stays On Safe Path 15/12/2017 by Catherine Saez, Intellectual Property Watch 1 Comment The mood was conciliatory this week at the World Intellectual Property Organization patent law committee as delegates mainly shared experiences and heard presentations. The five topics composing the work of the committee, which had been carefully negotiated in the summer and reflecting a “delicate balance” of interest between countries, will be pursued at the next session. Among them are the topics of patents and health, technology transfer, and the quality of patents.
Intellectual Property Rights In Trade – To Be Rethought? 15/12/2017 by Monika Ermert for Intellectual Property Watch Leave a Comment After two decades of intellectual property regimes in trade agreements, one could have some second thoughts, according to a number of panellists at the Trade and Sustainable Development Symposium, organised by the International Centre for Trade and Sustainable Development (ICTSD) and held alongside the 11th World Trade Organization Ministerial in Buenos Aires, Argentina this week.
London Declaration Report Shows Progress But More Needed Against Neglected Tropical Diseases 15/12/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment A newly released report by the wide-ranging joint London Declaration initiative to fight neglected tropical diseases shows progress in elimination of diseases and the number of people treated. However, in order to reach universal health coverage, efforts have to be intensified, according to the World Health Organization director general. The pharmaceutical industry, meanwhile, said it is ready to live up to its pledge made five years ago and expand donations programmes.
Former Medicines Patent Pool Head Greg Perry Joins Pharmaceutical Industry 15/12/2017 by Catherine Saez and William New, Intellectual Property Watch Leave a Comment A day after Greg Perry resigned as executive director of the Medicines Patent Pool, the pharmaceutical industry announced today that he will join the Geneva-based International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) as an assistant director general.
Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 by William New, Intellectual Property Watch 1 Comment After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.]
WIPO Delegates Told Patent Information Essential, Given Revealing Data On Medicines Access and Trade 14/12/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment World Intellectual Property Organization patent law committee delegates heard a number of presentations this week on the relationship between patents and health, and access to medicines. The importance of patent information and accurate, up-to-date databases was underlined, particularly for procurement. The weight of intellectual property rights on the issue of access to medicines and prices and generic market entry was pointed out, but so were other factors, such as the small percentage of new drugs with added benefit, tariffs, and trade delays.